Dashboard
1
Poor Management Efficiency with a low ROCE of 7.21%
- The company has been able to generate a Return on Capital Employed (avg) of 7.21% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
3
Healthy long term growth as Net Sales has grown by an annual rate of 81.43% and Operating profit at 80.15%
4
With ROE of 5.06%, it has a fair valuation with a 2.01 Price to Book Value
5
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
SEK 16,273 Million (Small Cap)
40.00
NA
0.00%
0.30
5.97%
2.15
Revenue and Profits:
Net Sales:
1,143 Million
(Quarterly Results - Jun 2025)
Net Profit:
94 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.99%
0%
-0.99%
6 Months
-28.88%
0%
-28.88%
1 Year
-32.87%
0%
-32.87%
2 Years
17.66%
0%
17.66%
3 Years
-9.43%
0%
-9.43%
4 Years
-50.84%
0%
-50.84%
5 Years
0%
0%
0.0%
Vimian Group AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
81.43%
EBIT Growth (5y)
80.15%
EBIT to Interest (avg)
3.45
Debt to EBITDA (avg)
2.40
Net Debt to Equity (avg)
0.22
Sales to Capital Employed (avg)
0.41
Tax Ratio
35.21%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.21%
ROE (avg)
3.39%
Valuation key factors
Factor
Value
P/E Ratio
40
Industry P/E
Price to Book Value
2.01
EV to EBIT
23.00
EV to EBITDA
15.22
EV to Capital Employed
1.77
EV to Sales
3.90
PEG Ratio
0.41
Dividend Yield
NA
ROCE (Latest)
7.70%
ROE (Latest)
5.06%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
1,143.00
1,207.60
-5.35%
Operating Profit (PBDIT) excl Other Income
274.00
361.70
-24.25%
Interest
17.50
84.30
-79.24%
Exceptional Items
-11.00
-79.80
86.22%
Consolidate Net Profit
94.20
52.80
78.41%
Operating Profit Margin (Excl OI)
154.40%
215.80%
-6.14%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -5.35% vs 0.15% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 78.41% vs -63.31% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
4,286.40
3,807.30
12.58%
Operating Profit (PBDIT) excl Other Income
1,075.00
963.50
11.57%
Interest
290.50
221.00
31.45%
Exceptional Items
-99.50
-100.70
1.19%
Consolidate Net Profit
220.70
120.30
83.46%
Operating Profit Margin (Excl OI)
160.90%
156.50%
0.44%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 12.58% vs 27.25% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 83.46% vs 257.05% in Dec 2023
About Vimian Group AB 
Vimian Group AB
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






